Loading…
Loading…
IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.
The iShares Global Healthcare ETF provides broader exposure with 110 holdings across various sub-sectors compared to the 26 positions in the VanEck Pharmaceutical ETF The VanEck Pharmaceutical ETF features a lower expense ratio of 0.36% and a higher trailing dividend yield of 2.00% While the iShares Global Healthcare ETF has experienced lower historical drawdowns, the VanEck Pharmaceutical ETF has delivered higher total returns over the last five years
PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.
iShares Global Healthcare ETF provides broad exposure to 110 global stocks while First Trust NYSE Arca Biotechnology Index Fund concentrates on 30 biotech positions. iShares Global Healthcare ETF carries a lower expense ratio of 0.40% compared to 0.55% for First Trust NYSE Arca Biotechnology Index Fund.
IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.
PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.
IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return.
iShares Global Healthcare ETF provides exposure to 110 international stocks, whereas iShares U.S. Pharmaceuticals ETF concentrates on 56 domestic companies iShares U.S. Pharmaceuticals ETF has higher concentration risk with its two largest holdings accounting for over 43.00% of the total portfolio iShares U.S. Pharmaceuticals ETF has outperformed on a one-year and five-year total return basis compared to iShares Global Healthcare ETF